High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Titel:
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Auteur:
Zwierenga, Fenneke van Veggel, Bianca Hendriks, Lizza E.L. Hiltermann, T. Jeroen N. Hiddinga, Birgitta I. Hijmering Kappelle, Lucie B.M. ter Elst, Arja Hashemi, Sayed M.S. Dingemans, Anne-Marie C. van der Leest, Cor de Langen, Adrianus J. van den Heuvel, Michel M. van der Wekken, Anthonie J.